218 related articles for article (PubMed ID: 15762353)
1. Treatment options in hormone-refractory metastatic prostate carcinoma.
Fusi A; Procopio G; Della Torre S; Ricotta R; Bianchini G; Salvioni R; Ferrari L; Martinetti A; Savelli G; Villa S; Bajetta E
Tumori; 2004; 90(6):535-46. PubMed ID: 15762353
[TBL] [Abstract][Full Text] [Related]
2. Treatment options in hormone-refractory prostate cancer: current and future approaches.
Harris KA; Reese DM
Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
[TBL] [Abstract][Full Text] [Related]
4. The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Samelis GF; Skarlos D; Bafaloukos D; Kosmidis P; Anagnostopoulos A; Aravantinos G; Dimopoulos MA;
Urology; 2003 Jun; 61(6):1211-5. PubMed ID: 12809899
[TBL] [Abstract][Full Text] [Related]
5. Controversies in chemotherapy of prostate cancer.
Heicappell R
Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
[No Abstract] [Full Text] [Related]
6. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
Garmey EG; Sartor O; Halabi S; Vogelzang NJ
Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
[TBL] [Abstract][Full Text] [Related]
7. NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Jilani A; George E; Adler AI
Lancet Oncol; 2012 Jun; 13(6):573-4. PubMed ID: 22833888
[No Abstract] [Full Text] [Related]
8. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
9. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
10. [Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
Johannsen M; Wilke K; Schnorr D; Loening SA
Urologe A; 2004 Feb; 43(2):160-7. PubMed ID: 14991117
[TBL] [Abstract][Full Text] [Related]
11. Update in the management of patients with hormone-refractory prostate cancer.
Moore CN; George DJ
Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191
[TBL] [Abstract][Full Text] [Related]
12. The management of hormone refractory prostate cancer.
Newling DW
Eur Urol; 1996; 29 Suppl 2():69-74. PubMed ID: 8717467
[TBL] [Abstract][Full Text] [Related]
13. The changing pattern of management for hormone-refractory, metastatic prostate cancer.
James ND; Bloomfield D; Luscombe C
Prostate Cancer Prostatic Dis; 2006; 9(3):221-9. PubMed ID: 16801939
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for hormone-refractory prostate cancer.
Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
Petrylak D
BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
17. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
18. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of hormone refractory prostate cancer: new standards, new trends].
Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
[TBL] [Abstract][Full Text] [Related]
20. The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
Petrylak DP
Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
